Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s): N.PFE

Healthcare

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Add To Watchlist

Recent & Breaking News (NYSE:PFE)

Investors: Option reports for Citigroup, The Gap, Nike, NVIDIA and Pfizer Inc. include trade ideas that offer returns of 18% or more!

PR Newswire May 22, 2017

The Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis

PR Newswire Europe Non Regulatory May 18, 2017

Astellas Announces Oncology Portfolio Updates

PR Newswire May 17, 2017

Pfizer Oncology to Present Data Across 13 Different Types of Cancer at ASCO 2017 Annual Meeting

Business Wire May 17, 2017

Pfizer Invites Public to View and Listen to Webcast of June 9 Conference Call with Analysts to Review Oncology Business and ASCO Data Presentations

Business Wire May 17, 2017

Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene Therapy

PR Newswire May 16, 2017

12 Biggest Mid-Day Gainers For Thursday

Benzinga.com May 11, 2017

Mid-Morning Market Update: Markets Open Lower; Macy's Profit Misses Expectations

Benzinga.com May 11, 2017

Covered Call reports for Apple, Coty Inc., NVIDIA, Pfizer Inc. and Yelp include trade ideas that offer returns of 21% or more!

PR Newswire May 11, 2017

A New ETF Is An Active Idea For Income

Benzinga.com May 11, 2017

20 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com May 11, 2017

Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy

PR Newswire May 10, 2017

FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer

PR Newswire Asia May 9, 2017

FDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer

PR Newswire May 9, 2017

Collaboration Helps Broaden Access to Pfizer’s Contraceptive, Sayana® Press (medroxyprogesterone acetate), for Women in Some of the World’s Poorest Countries

Business Wire May 8, 2017

Will TherapeuticsMD's Yuvvexy Pass The FDA Muster?

Benzinga.com May 7, 2017

Phase 3 OCTAVE Studies of Oral Tofacitinib in Ulcerative Colitis Results Published in The New England Journal of Medicine

Business Wire May 3, 2017

Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritis

Business Wire May 3, 2017

Mid-Afternoon Market Update: Crude Oil Down 2.5%; Chegg Surges Higher

Benzinga.com May 2, 2017

Mid-Day Market Update: Medpace Drops After Weak Earnings; Angie's List Shares Spike Higher

Benzinga.com May 2, 2017